Results 261 to 270 of about 11,284,409 (311)

L-Dopa and Parkinsonism

Nature, 1970
This new treatment for an old disease has its origins in pharmacological research of the late 1950s. There is still not full agreement about how L-dopa functions in the nervous system, but, as this review shows, there is ample evidence to support the clinical work in progress since 1961.
D B, Calne, M, Sandler
openaire   +2 more sources

l-dopa and pancreatic secretion

Biochemical Pharmacology, 1973
Abstract Greengard , Roback and Ivy (1942) first observed that epinine ( N -methyldopamine), dopamine (dihydroxyphenylethylamine) and few phenylethylamine derivatives given intravenously stimulated the canine pancreatic secretion, while the majority of sympathomimetic amines tested inhibited it.
KOROKU HASHIMOTO, YASUHIKO FURUTA, KAZUHIKO IWATSUKI   +2 more
openaire   +1 more source

Effect of L‐Dopa on Polycythemia

Journal of the American Geriatrics Society, 1977
ABSTRACT A patient with Parkinson's disease, in whom polycythemia vera was known to be present for several years prior to the onset of parkinsonian symptoms, received treatment with a preparation consisting of L‐dopa plus a decarboxylase inhibitor (Madopar).
Y, Herishanu, P, Rosenberg
openaire   +2 more sources

Microbiological Synthesis of L-dopa

Journal of Pharmaceutical Sciences, 1974
The ability of microorganisms to convert N-carbobenzoxyl-L-tyrosine, N-tert-butyloxycarbonyl-L-tyrosine, and N-formyl-L-tyrosine into their respective N-substituted L-dopa derivatives was studied. These tyrosine derivatives were examined because of the ease with which the blocking groups may be removed.
J, Rosazza, P, Foss, M, Lemberger, C J, Sih   +3 more
openaire   +2 more sources

Parkinsonism, L-Dopa and Intelligence

American Journal of Psychiatry, 1973
Although many patients with parkinsonism undergo a significant amount of intellectual impairment, several investigators, including the authors, have observed an improvement in intellectual functioning during the first year of treatment with L-dopa. Upon reexamining subjects after 30 months of treatment, however, the authors found that most of their ...
A W, Loranger, H, Goodell, F H, McDowell, J E, Lee, R D, Sweet   +4 more
openaire   +2 more sources

Effects of L-dopa in autism

Journal of Autism and Childhood Schizophrenia, 1971
A study was designed to determine if blood serotonin concentrations could be lowered in autistic children by the administration of L-dopa and, if so, to observe possible clinical or physiological changes. Following a 17-day placebo period, four hospitalized autistic boys (3, 4, 9, and 13 years of age) received L-dopa for 6 months.
E R, Ritvo, A, Yuwiler, E, Geller, A, Kales, S, Rashkis, A, Schicor, S, Plotkin, R, Axelrod, C, Howard   +8 more
openaire   +2 more sources

Molecular conformation of L-DOPA

Biochemical and Biophysical Research Communications, 1970
Abstract The structure of L-DOPA, a biological precursor of melanins has been determined by a new systematic analysis of the Patterson function. Its molecular conformation is different from that so far reported for any aromatic aminoacid, peptide or related compound.
J W, Becker, Y T, Thathachari, P G, Simpson   +2 more
openaire   +2 more sources

L-DOPA IN IDIOPATHIC PARKINSONISM

The Lancet, 1969
Abstract Twenty-six patients with idiopathic parkinsonism were admitted to a " double blind " " within-patient " comparison between oral L-dopa and placebo. Twenty patients completed the programme. The intake of L-dopa was gradually increased to maximum tolerated dosage (1-8 g.
D B, Calne, G M, Stern, A S, Spiers, D R, Laurence   +3 more
openaire   +2 more sources

Effect of L‐Dopa in Schizophrenia

Psychiatry and Clinical Neurosciences, 1972
SummaryL‐Dopa was administered to 84 cases of schizophrenia (55 male, 29 female) together with major tranquilizers which had been given previously.1) Patients suffering from lack of spontaneity, abulia, apathy, and disturbance of rapport were chosen as subjects in this research.
K, Inanaga, K, Inoue, H, Tachibana, M, Oshima, T, Kotorii   +4 more
openaire   +2 more sources

L-DOPA IN POSTENCEPHALITIC PARKINSONISM

The Lancet, 1969
Abstract Treatment of postencephalitic parkinsonism with oral L-dopa administered over 6 weeks in maximum tolerated doses has been studied in a between-patient double-blind therapeutic trial, involving 40 patients. 7 of the 20 patients receiving L-dopa improved substantially and 3 moderately; 5 showed no useful response, and 5 had to stop L-dopa ...
D B, Calne, G M, Stern, D R, Laurence, J, Sharkey, P, Armitage   +4 more
openaire   +2 more sources